What’s Going On With Baidu Shares Today?

Baidu Inc (NASDAQ: BIDU) shares are trading higher on Tuesday.

Baidu Inc (NASDAQ:BIDU) shares are trading higher on Tuesday. The company announced plans to build the world’s largest fully driverless ride-hailing service area in 2023.

What To Know: During the company’s autonomous driving tech event, Baidu announced plans to expand the operation area for its fully driverless robotaxis, allowing the company to reach more potential customers.

Baidu also revealed a series of new technological advancements including an AI model built for autonomous driving perception, autonomous driving maps, a closed-loop autonomous driving data system and AI chips for autonomous vehicles.

What Else: Baidu shares are also trading higher amid hopes that protests in China could spark an easing of COVID restrictions.

A Chinese official said authorities will continue to adjust policies to reduce the impacts of current restrictions, per Reuters.

A separate report indicates that Beijing has started to pare back COVID restrictions. A local official in the capital reportedly said restrictions imposed to identify those infected shouldn’t exceed 24 hours. Beijing also plans to ramp up vaccination efforts among the elderly. Xinjiang officials noted that they will lift lockdowns in designated areas as soon as possible.

See Also: Alibaba Stock Is Rising Today: What’s Going On?

BIDU Price Action: Baidu has a 52-week high of $171.87 and a 52-week low of $73.58.

The stock was up 6.33% at $100.64 at time of publication, according to Benzinga Pro.

Photo: Automobile Italia from Flickr.

Total
0
Shares
Related Posts
Read More

Nexcella, A Subsidiary Of Immix Biopharma, Presents 42-Patient Interim Data, With 90% Overall Response Rate In Relapsed Or Refractory Multiple Myeloma At NXC-201 Therapeutic Dose From Its Phase 1 Expansion Trial At The 5th European Car T-Cell Meeting

The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated with NXC-201 (formerly HBI0101), of which 29 received the therapeutic dose of 800 million CAR+T cells as of the

IMMX